Company Overview - Awei Technology's closing price on August 8 was 28.98 yuan, up 7.25%, with a rolling PE ratio of 81.80, marking a new low in 861 days, and a total market capitalization of 1.971 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 55.70 and a median of 39.08, placing Awei Technology at the 101st position in the industry ranking [1] - As of the first quarter of 2025, two institutions held shares in Awei Technology, with a total of 104,200 shares valued at 0.02 million yuan [1] Business Operations - Awei Technology specializes in the research, development, production, sales, and service of medical clinical testing analysis instruments, in vitro diagnostic reagents, and medical consumables [1] - The company has a total of 259 authorized patents (including 97 domestic invention patents and 18 overseas patents) and 30 software copyrights as of December 31, 2024 [1] - The company holds 78 first-class medical device registration certificates, 72 second-class medical device registration certificates, and 4 third-class medical device registration certificates [1] - In July 2024, Awei Technology was recognized as the "Changsha Machine Vision Technology Automatic Microscope Morphological Testing Technology Innovation Center" [1] Financial Performance - In the first quarter of 2025, Awei Technology reported revenue of 53.2953 million yuan, a year-on-year increase of 13.85%, and a net profit of 6.3210 million yuan, up 24.63%, with a gross profit margin of 55.59% [1]
爱威科技收盘上涨7.25%,滚动市盈率81.80倍,总市值19.71亿元